UNLIMITED TURBO LONG - CHARLES RIVER LABS INTL Share Price

Certificat

DE000PC6FHA9

Real-time Bid/Ask 16:37:40 21/05/2024 BST
6.48 EUR / 6.58 EUR -1.36% Intraday chart for UNLIMITED TURBO LONG - CHARLES RIVER LABS INTL
Current month-10.42%
1 month-8.44%
Date Price Change
21/05/24 6.53 -1.36%
20/05/24 6.62 +2.95%
17/05/24 6.43 -5.99%
16/05/24 6.84 -10.12%
15/05/24 7.61 +0.53%

Delayed Quote Börse Stuttgart

Last update May 21, 2024 at 04:17 pm

More quotes

Static data

Product typeCertificat Turbo
Buy / SellCALL
Underlying CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
IssuerLogo Issuer BNP Paribas BNP Paribas
WKN PC6FHA
ISINDE000PC6FHA9
Date issued 12/03/2024
Strike 152.7 $
Maturity Unlimited
Parity 10 : 1
Emission price 11.1
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 11.57
Lowest since issue 6.43
Spread 0.1
Spread %1.51%

Company Profile

Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (63.4%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (19.2%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (17.5%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (83.3%) and sales of products (16.7%). Net sales are distributed geographically as follows: the United States (56.8%), Europe (26%), Canada (11.8%), Asia/Pacific (4.9%) and other (0.4%).
Sector
-
More about the company

Ratings for Charles River Laboratories International, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Charles River Laboratories International, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
223.1 USD
Average target price
265.6 USD
Spread / Average Target
+19.07%
Consensus